PremiumThe FlySurrozen to discontinue development of SZN-043 in alcohol associated hepatitis Meta Platforms, CVS Health upgraded: Wall Street’s top analyst calls Surrozen initiated with a Buy at H.C. Wainwright PremiumThe FlySurrozen reports Q3 EPS (44c) vs. ($5.14) last year Surrozen, TCGFB announce strategic research collaboration Surrozen earns $10M milestone payment in Retinal Diseases collaboration PremiumThe FlySurrozen presents data demonstrating potentialfor Wnt mimetic technologies Surrozen files to sell 1.09M shares of common stock for holders Patent Battles: Surrozen, Inc. at Risk of Financial Instability Amid IP Challenges 
